Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Amylyx Pharmaceuticals | AMLX | Nov 13, 2024 | 5.68 | -8.97 |
AN2 Therapeutics | ANTX | Nov 13, 2024 | 1.01 | -4.72 |
Analog Devices | ADI | Nov 13, 2024 | 212.84 | -3.06 |
AnaptysBio | ANAB | Nov 13, 2024 | 20.75 | -3.49 |
Anavex Life Sciences | AVXL | Nov 13, 2024 | 8.89 | -1.44 |
Andretti Acquisition II | POLE | Nov 13, 2024 | 9.97 | 0.00 |
Andretti Acquisition II Unit | POLEU | Nov 13, 2024 | 10.00 | 0.00 |
Anebulo Pharmaceuticals | ANEB | Nov 13, 2024 | 1.55 | -6.06 |
ANEW Medical | WENA | Nov 13, 2024 | 0.73 | 0.00 |
Angel Oak Financial Strategies | FINS | Nov 13, 2024 | 12.79 | -0.54 |
Angel Oak Mortgage REIT | AOMR | Nov 13, 2024 | 10.02 | +1.11 |
Anghami | ANGH | Nov 13, 2024 | 0.75 | -1.25 |
Angi A | ANGI | Nov 13, 2024 | 1.85 | -4.40 |
AngioDynamics | ANGO | Nov 13, 2024 | 6.99 | -2.10 |
Anglogold Ashanti | AU | Nov 13, 2024 | 24.12 | -2.07 |
Anheuser-Busch InBev ADR | BUD | Nov 13, 2024 | 55.80 | -0.36 |
ANI Pharmaceuticals | ANIP | Nov 13, 2024 | 59.83 | -1.92 |
Anika Therapeutics | ANIK | Nov 13, 2024 | 17.04 | +0.95 |
Anixa Biosciences | ANIX | Nov 13, 2024 | 3.10 | -4.62 |
Annaly Capital Management | NLY | Nov 13, 2024 | 19.62 | +0.72 |
Annaly Capital Management F Pref | NLY-F | Nov 13, 2024 | 25.95 | +0.15 |
Annaly Capital Management G Pref | NLY-G | Nov 13, 2024 | 25.58 | +0.39 |
Annaly Capital Management I Pref | NLY-I | Nov 13, 2024 | 25.92 | +0.58 |
Annexon | ANNX | Nov 13, 2024 | 6.55 | -0.91 |
Annovis Bio | ANVS | Nov 13, 2024 | 7.41 | -1.72 |
ANSYS | ANSS | Nov 13, 2024 | 344.10 | -0.11 |
Antelope Enterprise | AEHL | Nov 13, 2024 | 0.30 | +0.44 |
Anterix | ATEX | Nov 13, 2024 | 33.62 | -0.47 |
Antero Midstream | AM | Nov 13, 2024 | 15.04 | -2.40 |
Antero Resources | AR | Nov 13, 2024 | 31.19 | +0.10 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.